The Coagulation Factor XI pipeline drugs market research report outlays comprehensive information on the Coagulation Factor XI targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses the drugs in the Coagulation Factor XI pipeline by therapy areas, indications, stages, MoA, RoA, molecule type and the key players in the development pipeline. Buy the report here.

The report also covers products from therapy areas such as Cardiovascular, Hematological Disorders, Genito Urinary System, and Central Nervous System which include the indications Thrombosis, Venous Thromboembolism, Bleeding And Clotting Disorders, Hemophilia C (Factor XI Deficiency), End-Stage Kidney Disease (End-Stage Renal Disease or ESRD), and Intracerebral Hemorrhage. It also reviews key players involved in Coagulation Factor XI targeted therapeutics development with respective active and dormant or discontinued products.

The Coagulation Factor XI pipeline targets constitutes close to 31 molecules. Out of which, approximately 30 molecules are developed by companies and the remaining by the universities/institutes. The molecules developed by companies in Phase III, Phase II, Phase I, IND/ CTA Filed, and Preclinical stages are 3, 8, 10, 2, and 7 respectively. Similarly, the universities portfolio in Preclinical comprises 1 molecule.

Coagulation Factor XI overview

Factor XI or plasma thromboplastin antecedent is the zymogen form of factor Xia. Factor XI triggers the middle phase of the intrinsic pathway of blood coagulation by activating factor IX. Inhibitors of factor XIa include protein Z-dependent protease inhibitor.

For a complete picture of Coagulation Factor XI’s drug pipeline, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third-party sources.

Drug profiles featured in the report undergo periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.